Page 1279 - Williams Hematology ( PDFDrive )

1254 Part IX: Lymphocytes and Plasma Cells Chapter 81: Hematologic Manifestations of Acquired Immunodeficiency Syndrome 1255

HIV– patients, treatment with intravenous anti-D increased the plate- REFERENCES
let count by an average of 45,000/μL in adults in both groups. In the
majority of patients, the platelet increment lasted more than 21 days. 1. Sharp PM, Hahn BH: Origins of HIV and the AIDS pandemic. Cold Spring Harb Per-
spect Med 1:a006841, 2011.
The major side effect of anti-D treatment was a drop in the hemoglobin 2. Worobey M, Gemmel M, Teuwen DE, et al: Direct evidence of extensive diversity of
(average decrease in hemoglobin of 1 g/dL). Another approach is to use HIV-1 in Kinshasa by 1960. Nature 455:661–664, 2008.
intravenous immunoglobulin although one study of immunoglobulin 3. Gallo RC, Sarin PS, Gelmann EP, et al: Isolation of human T-cell leukemia virus in
acquired immune deficiency syndrome (AIDS). Science 220:865–867, 1983.
treatment reported a smaller increase in the platelet count (average 4. Barre-Sinoussi F, Chermann JC, Rey F, et al: Isolation of a T-lymphotropic retrovi-
of 29,000/μL), and a shorter duration of response (19 days) than was rus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science
283
obtained with intravenous anti-D. Furthermore, intravenous anti-D 220:868–871, 1983.
may be less expensive than intravenous immunoglobulin. However, 5. de Silva TI, Cotten M, Rowland-Jones SL: HIV-2: The forgotten AIDS virus. Trends
Microbiol 16:588–595, 2008.
anti-D has the potential to cause significant hemolysis and has a “Black 6. de Silva TI, van Tienen C, Onyango C, et al: Population dynamics of HIV-2 in rural
Box” warning because of this rare complication. Alternative approaches West Africa: Comparison with HIV-1 and ongoing transmission at the heart of the
include the use of standard doses of prednisone or pulse dexametha- epidemic. AIDS 27:125–134, 2013.
sone, as in HIV– patients. Steroids are less attractive in HIV+ patients 7. Centers for Disease Control (CDC): Follow-up on Kaposi’s sarcoma and Pneumocystis
pneumonia. MMWR Morb Mortal Wkly Rep 30:409–410, 1981.
because of the potential to decrease CD4 counts, increase the risk of 8. Centers for Disease Control (CDC): Kaposi’s sarcoma and Pneumocystis pneumonia
infection, and increase risk of Kaposi sarcoma progression. Splenec- among homosexual men—New York City and California. MMWR Morb Mortal Wkly
Rep 30:305–308, 1981.
tomy can be effective in HIV+ patients, but is rarely required. Case 9. Centers for Disease Control (CDC): Pneumocystis pneumonia—Los Angeles. MMWR
284
reports document the use of romiplostim or eltrombopag in HIV+ Morb Mortal Wkly Rep 30:250–252, 1981.
patients. 285,286 10. Jaffe HW, Bregman DJ, Selik RM: Acquired immune deficiency syndrome in the United
HIV+ patients with ITP should be counseled not to take aspirin or States: The first 1,000 cases. J Infect Dis 148:339–345, 1983.
nonsteroidal antiinflammatory drugs or fish oil while severely throm- 11. Centers for Disease Control (CDC): Pneumocystis carinii pneumonia among persons
with hemophilia A. MMWR Morb Mortal Wkly Rep 31:365–367, 1982.
bocytopenic, and educated on the symptoms of relapse of ITP (spon- 12. Centers for Disease Control (CDC): Possible transfusion-associated acquired immune
taneous nose bleeds, spontaneous large bruises, bleeding gums), and deficiency syndrome (AIDS)—California. MMWR Morb Mortal Wkly Rep 31:652–654,
1982.
encouraged to report promptly for medical care should any of these 13. Leads from the MMWR. Prevention of acquired immune deficiency syndrome (AIDS):
occur. Most patients with HIV-associated ITP can be started on ART Report of inter-agency recommendations. JAMA 249:1544–1545, 1983.
and treated with 1 or 2 doses of anti-D at 3-week intervals and will sub- 14. Centers for Disease Control (CDC): Immunodeficiency among female sexual partners
sequently experience sustained platelet count response with effective of males with acquired immune deficiency syndrome (AIDS)—New York. MMWR
Morb Mortal Wkly Rep 31:697–698, 1983.
control of HIV. 15. Centers for Disease Control (CDC): Update: Acquired immunodeficiency syndrome
(AIDS) among patients with hemophilia—United States. MMWR Morb Mortal Wkly
Rep 32:613–615, 1983.
HUMAN IMMUNODEFICIENCY 16. Pape JW, Liautaud B, Thomas F, et al: The acquired immunodeficiency syndrome in
Haiti. Ann Intern Med 103:674–678, 1985.
VIRUS–ASSOCIATED NEUTROPENIA 17. Pape JW, Liautaud B, Thomas F, et al: Characteristics of the acquired immunodeficiency
The prevalence of neutropenia (defined as a neutrophil count <1300/μL) syndrome (AIDS) in Haiti. N Engl J Med 309:945–950, 1983.
in patients naïve to ART in Africa, Asia, the Americas, and the Carib- 18. De Cock KM, Jaffe HW, Curran JW: The evolving epidemiology of HIV/AIDS. AIDS
26:1205–1213, 2012.
bean was 14.3 percent, with the U.S. cohort having a slightly higher 19. Quinn TC, Wawer MJ, Sewankambo N, et al: Viral load and heterosexual transmission
287
prevalence of approximately 16 percent. A multicenter prospective of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med
study of HIV+ women in the United States followed 1729 women 342:921–929, 2000.
288
and found that 7 percent had a pre-ART absolute neutrophil count of 20. Patel P, Borkowf CB, Brooks JT, et al: Estimating per-act HIV transmission risk: A sys-
tematic review. AIDS 28:1509–1519, 2014.
less than 1000/μL, and during 7.5 years of follow up 31 percent had an 21. Bar M, Wyman SK, Fritz BR, et al: MicroRNA discovery and profiling in human embry-
absolute neutrophil count of less than 1000/μL. Low CD4 count and onic stem cells by deep sequencing of small RNA libraries. Stem Cells 26:2496–2505,
2008.
high viral load were significant risk factors for development of neutro- 22. Cohen MS, Chen YQ, McCauley M, et al: Prevention of HIV-1 infection with early
penia whereas initiation of ART correlated with resolution of neutro- antiretroviral therapy. N Engl J Med 365:493–505, 2011.
penia. Patients living with HIV may have neutropenia for a variety of 23. Hladik F, McElrath MJ: Setting the stage: Host invasion by HIV. Nat Rev Immunol
reasons and neutropenia may be a component of pancytopenia (see 8:447–457, 2008.
Table 81–10) or occur as an isolated finding. As discussed in the sec- 24. Hu Q, Frank I, Williams V, et al: Blockade of attachment and fusion receptors inhibits
HIV-1 infection of human cervical tissue. J Exp Med 199:1065–1075, 2004.
tion “Pathophysiology of Anemia in HIV” above, HIV has a multitude 25. Borrow P: Innate immunity in acute HIV-1 infection. Curr Opin HIV AIDS 6:353–363,
of effects on hematopoiesis, and the effects on progenitor cell survival, 2011.
growth and differentiation and on the marrow microenvironment per- 26. Cohen MS, Shaw GM, McMichael AJ, et al: Acute HIV-1 Infection. N Engl J Med
364:1943–1954, 2011.
tain to myelopoiesis as well as erythropoiesis and megakaryopoiesis. 27. Wei X, Decker JM, Wang S, et al: Antibody neutralization and escape by HIV-1. Nature
A study of 87 consecutive patients attending an HIV clinic who devel- 422:307–312, 2003.
oped an absolute neutrophil count of less than 1000/μL showed that 28. Borrow P, Lewicki H, Hahn BH, et al: Virus-specific CD8+ cytotoxic T-lymphocyte
activity associated with control of viremia in primary human immunodeficiency virus
the vast majority were receiving at least one known myelosuppressive type 1 infection. J Virol 68:6103–6110, 1994.
medication, and 59 of the 87 patients were receiving three or more 29. Borrow P, Lewicki H, Wei X, et al: Antiviral pressure exerted by HIV-1-specific cyto-
myelosuppressive drugs. Many other medications are rare causes of toxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection
of CTL escape virus. Nat Med 3:205–211, 1997.
289
neutropenia, illustrating the importance of drug-induced neutrope- 30. Cao J, McNevin J, Malhotra U, et al: Evolution of CD8+ T cell immunity and viral
nia in this population of patients. escape following acute HIV-1 infection. J Immunol 171:3837–3846, 2003.
Other causes of neutropenia reported in HIV+ patients include defi- 31. Schmitz JE, Kuroda MJ, Santra S, et al: Control of viremia in simian immunodeficiency
virus infection by CD8+ lymphocytes. Science 283:857–860, 1999.
ciency of vitamins such as folate or vitamin B , hepatitis C-associated 32. Ganusov VV, Goonetilleke N, Liu MK, et al: Fitness costs and diversity of the cyto-
12
autoimmune neutropenia, alcohol toxicity, and levamisole-adulterated toxic T lymphocyte (CTL) response determine the rate of CTL escape during acute and
cocaine, which can cause severe neutropenia (neutrophil counts as low as chronic phases of HIV infection. J Virol 85:10518–10528, 2011.
0). Patients should be specifically asked about cocaine use if they are found 33. Goonetilleke N, Liu MK, Salazar-Gonzalez JF, et al: The first T cell response to transmit-
to have severe neutropenia with normal hemoglobin and platelet count. 290 ted/founder virus contributes to the control of acute viremia in HIV-1 infection. J Exp
Med 206:1253–1272, 2009.

Kaushansky_chapter 81_p1239-1260.indd 1254 9/21/15 11:19 AM